Gary Patou, Director at Xenon Pharmaceuticals Inc. (XENE), sold 1,322 shares at $53.14 ($70K) on 2026-06-05, disclosed to the SEC on 2026-06-08.
Scheduled sale ($70k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| XENE | SELL | 2023-12-15 | $624K | — | Filing → |
| XENE | SELL | 2022-11-28 | $276K | — | Filing → |
| XENE | BUY | 2017-08-14 | $21K | — | Filing → |